EE3 Cost-Utility Analysis of Xelox Plus Bevacizumab Versus Xelox for Metastatic Colorectal Cancer Treatment in Thailand
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.258
https://www.valueinhealthjournal.com/article/S1098-3015(22)02462-7/fulltext
Title :
EE3 Cost-Utility Analysis of Xelox Plus Bevacizumab Versus Xelox for Metastatic Colorectal Cancer Treatment in Thailand
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02462-7&doi=10.1016/j.jval.2022.09.258
First page :
Section Title :
Open access? :
No
Section Order :
12064